News – Page 83 – Endpoints News

MacroGenics pauses development of ADC; Cellectis deprioritizes CAR-T

7 months ago

Biotech industry worries over potential for RFK Jr. ally as FDA pick

7 months ago

At this year's ObesityWeek, GLP-1s aren’t the only talk of the town

7 months ago

New Trump era could be a boon for biopharma M&A, dealmaking

7 months ago

Novo unveils new cardiometabolic data as it reports solid third-quarter profits

7 months ago

Acadia lands $150M sale of rare pediatric PRV

7 months ago

‘We’re good’ on weight loss: Biopharmas turn to muscle with new obesity drugs

7 months ago

One biotech is looking to lessen antipsychotic-induced weight gain, despite new entrants

7 months ago

Cerebral to pay nearly $3.7M over controlled substance prescribing practices

7 months ago

Catalent touts customer confidence ahead of Novo deal, but misses revenue estimates

7 months ago

Novo Nordisk takes Forma’s sickle cell treatment into Phase 3

7 months ago

Zealand’s ‘aspirational’ mission for its amylin drug to be first-line in obesity

7 months ago

J&J's Darzalex hits primary endpoint in Phase 3 early-stage multiple myeloma trial

7 months ago

Gilead and Arcellx spotlight safety of multiple myeloma cell therapy, dose first patient in Phase 3

7 months ago

Sanofi reveals positive data for BTK inhibitor from $3.7B Principia takeover

7 months ago

Syndax inks a $350M royalty deal; FDA pushes back decision on Organon’s eczema drug

7 months ago

Beam discloses first clinical data on base-edited sickle cell therapy, one patient death

7 months ago

PrognomiQ raises $34M for lung cancer test

7 months ago

Updated: Vertex makes money from gene-edited therapy Casgevy

7 months ago

Nektar divests manufacturing site and reagent arm for $90M

7 months ago

Why hospitals have been slow to adopt AI for medical care

7 months ago

Sana narrows focus again to zero in on diabetes and autoimmune disease

7 months ago

Viking CEO on ‘shocking’ market reaction to oral obesity data, preparing for Phase 3

7 months ago

FDA cites Mark Cuban's drug compounding center in Dallas with sterility, quality concerns

7 months ago

First page Previous page 80 81 828384 85 86 Next page Last page